Dipeptidyl peptidase inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8329900
APP PUB NO 20080108808A1
SERIAL NO

11929673

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising:

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
TAKEDA PHARMACEUTICAL COMPANY LIMITEDOSAKA674

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Elder, Bruce J Wynantskill, US 10 144
Feng, Jun Carlsbad, US 83 1149
Gwaltney, Stephen L San Diego, US 37 437
Isbester, Paul K Castleton, US 20 181
Palmer, Grant J Clifton Park, US 19 182
Salsbury, Jonathon S Albany, US 15 118
Stafford, Jeffrey A San Diego, US 78 914
Ulysse, Luckner G Albany, US 8 122
Zhang, Zhiyuan San Diego, US 48 773

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (9)
2003/0060,434 COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS 20 1999
2002/0061,839 Serine peptidase modulators 29 2001
2002/0037,829 Use of DPPIV inhibitors as diuretic and anti-hypertensive agents 34 2001
2002/0165,164 New effectors of dipeptidyl peptidase IV for topical use 29 2002
2002/0193,390 Pharmaceutical compositions containing an N-(substituted glycyl)-2-cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV 35 2002
2003/0139,434 Combinations comprising dipeptidylpeptidase-iv inhibitor 42 2002
2003/0171,358 New compounds, their preparation and use 27 2003
2008/0108,807 DIPEPTIDYL PEPTIDASE INHIBITORS 17 2007
2008/0108,808 DIPEPTIDYL PEPTIDASE INHIBITORS 17 2007
 
NOVOZYMES BIOTECH, INC. (1)
6184020 Polypeptides having aminopeptidase activity and nucleic acids encoding same 29 1998
 
NOVARTIS AG (10)
6011155 N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV 126 1997
6107317 N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV 58 1999
6110949 N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV 85 1999
6172081 Tetrahydroisoquinoline 3-carboxamide derivatives 65 1999
6124305 Use of N-(substituted glycyl)-2-cyanopyrrolidines in inhibiting dipeptidyl peptidase-IV 69 1999
6166063 N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV 138 1999
6617340 N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV 56 2000
6559188 Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes 50 2000
6608038 Methods and compositions for treatment of diabetes and related conditions via gene therapy 34 2001
6432969 N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV 86 2001
 
TORRENT PHARMACEUTICALS LIMITED (1)
2004/0106,802 Novel compounds and therapeutic uses thereof 36 2003
 
SYITX, INC. (1)
2004/0254,226 Dipeptidyl peptidase inhibitors 45 2004
 
RHODE ISLAND HOSPITAL (1)
6129911 Liver stem cell 49 1998
 
PFIZER INC. (6)
2003/0166,662 Treatment of the insulin resistance syndrome 29 2003
6710040 Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors 52 2003
2004/0110,817 Dipeptidyl peptidase IV inhibiting fluorinated cyclic amides 53 2003
2004/0132,713 Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors 28 2003
2004/0242,898 Synthesis of 3,3,4,4-tetrafluoropyrrolidine and novel dipeptidyl peptidase-IV inhibitor compounds 43 2004
2005/0043,292 Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors 49 2004
 
TAKEDA PHARMACEUTICAL COMPANY LIMITED (16)
2004/0242,568 Dipeptidyl peptidase inhibitors 30 2004
2004/0259,870 Dipeptidyl peptidase inhibitors 29 2004
2005/0065,148 Dipeptidyl peptidase inhibitors 20 2004
2005/0070,531 Dipeptidyl peptidase inhibitors 20 2004
2005/0070,535 Dipeptidyl peptidase inhibitors 21 2004
2005/0070,706 Dipeptidyl peptidase inhibitors 19 2004
2005/0075,330 Dipeptidyl peptidase inhibitors 19 2004
2005/0065,144 Dipeptidyl peptidase inhibitors 43 2004
2005/0065,145 Dipeptidyl peptidase inhibitors 54 2004
* 7807689 Dipeptidyl peptidase inhibitors 7 2005
2006/0135,767 Dipeptidyl peptidase inhibitors 36 2005
2007/0060,528 ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS 21 2006
2007/0060,530 ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS 59 2006
2007/0066,635 POLYMORPHS OF BENZOATE SALT OF 2-[[6-[(3R)-3-AMINO-1-PIPERIDINYL]-3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1(2H)-P-YRIMIDINYL]METHYL]-BENZONITRILE AND METHODS OF USE THEREFOR 19 2006
* 7795428 Dipeptidyl peptidase inhibitors 8 2007
* 7781584 Dipeptidyl peptidase inhibitors 12 2007
 
ELI LILLY AND COMPANY (5)
5512549 Glucagon-like insulinotropic peptide analogs, compositions, and methods of use 182 1994
5614379 Process for preparing anti-obesity protein 70 1995
6006753 Use of GLP-1 or analogs to abolish catabolic changes after surgery 138 1997
6555521 Glucagon-like peptide-1 crystals 58 2001
2003/0060,412 Process for solubilizing glucagon-like peptide 1compounds 30 2002
 
MITSUBISHI PHARMA CORPORATION (1)
2004/0259,883 Thiazolidine derivative and medicinal use thereof 52 2004
 
ZP HOLDING SPV K/S (1)
6528486 Peptide agonists of GLP-1 activity 95 2000
 
OTSUKA PHARMACEUTICAL FACTORY, INC. (1)
5798344 Phosphonic ester derivatives of quinazolinones 41 1996
 
PROSIDION LIMITED (16)
6548481 Effectors of dipeptidyl peptidase IV 112 2000
6500804 Method for the improvement of islet signaling in diabetes mellitus and for its prevention 49 2001
2002/0006,899 Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals 59 2001
2002/0071,838 Method for raising the blood glucose level in mammals 36 2001
2002/0110,560 Use of dipeptidyl peptidase IV effectors for normalizing the blood glucose level in mammals 40 2002
2003/0135,023 Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis 36 2002
2002/0198,242 Method for the improvement of islet signaling in diabetes mellitus and for its prevention 33 2002
2003/0008,905 Method for the improvement of islet signaling in diabetes mellitus and for its prevention 33 2002
2003/0176,357 Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels 45 2002
2003/0148,961 Peptidyl ketones as inhibitors of DPIV 35 2002
2004/0058,876 Secondary binding site of dipeptidyl peptidase IV (DP IV) 31 2002
2003/0125,304 Substituted amino ketone compounds 49 2002
2003/0134,802 Novel effectors of dipepetidyl peptidase IV 49 2003
2003/0232,761 Novel analogues of glucose-dependent insulinotropic polypeptide 37 2003
2004/0229,848 Glutaminyl based DP IV-inhibitors 44 2004
2005/0014,946 Substituted amino ketone compounds 28 2004
 
HOFFMANN-LA ROCHE INC. (5)
6861440 DPP IV inhibitors 49 2002
6727261 Pyrido[2,1-A]Isoquinoline derivatives 84 2002
6867205 Pyridine and pyrimidine derivatives 44 2003
6800650 Pyridine and quinoline derivatives 48 2003
2004/0259,902 Pyrido [2,1-a] isoquinoline derivatives 44 2004
 
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (8)
2002/0155,565 FAP-activated anti-tumor compounds 28 2001
2003/0055,052 FAP-activated anti-tumor compounds 28 2001
2002/0198,205 Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions 120 2002
2004/0166,125 Xanthine derivatives, their preparation and their use in pharmaceutical compositions 85 2003
2004/0087,587 Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions 112 2003
2004/0138,214 Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions 111 2003
2004/0138,215 Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions 87 2003
2004/0077,645 Xanthine derivatives,production and use thereof as medicament 117 2003
 
NEWCASTLE UNIVERSITY VENTURES LIMITED (A COMPANY INCORPORATED IN ENGLAND) (1)
6156739 Quinazolinone compounds 37 1999
 
EISAI CO., LTD. (1)
2004/0116,328 Condensed imidazole derivatives 112 2003
 
MERCK SHARP & DOHME CORP. (1)
6699871 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 111 2002
 
TAKEDA PHARMACEUTICAL COMPANY, INC. (1)
2008/0003,283 DIPEPTIDYL PEPTIDASE INHIBITORS 21 2007
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2)
6235493 Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue 50 1998
6448045 Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1 24 2000
 
BRISTOL-MYERS SQUIBB COMPANY (9)
6548529 Heterocyclic containing biphenyl aP2 inhibitors and method 93 2000
6555519 O-glucosylated benzamide SGLT2 inhibitors and method 61 2001
6620821 HMG-CoA reductase inhibitors and method 57 2001
6627636 HMG-CoA reductase inhibitors and method 38 2001
6727271 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method 38 2002
6573287 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method 53 2002
6673815 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method 45 2002
2004/0009,972 Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase 66 2003
2004/0132,732 Quinazolinones and derivatives thereof as factor Xa inhibitors 33 2003
 
BOEHRINGER INGELHEIM INTERNATIONAL GMBH (1)
2005/0026,921 New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions 97 2004
 
CORNELL UNIVERSITY (1)
5811281 Immortalized intestinal epithelial cell lines 30 1994
 
PROBIODRUG AG (1)
2003/0130,199 Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents 55 2002
 
MACRONIX INTERNATIONAL CO., LTD. (1)
2003/0089,935 Non-volatile semiconductor memory device with multi-layer gate insulating structure 29 2001
 
114936 ONTARIO INC. (1)
2003/0040,478 Chemotherapy treatment 29 2002
 
Vaccinogen, Inc. (1)
5433955 Site specific in vivo activation of therapeutic drugs 69 1993
 
MERCK & CO., INC. (1)
5387512 Preparation of 3-[z-benzoxazol-2-yl)ethyl]-5-(1-hydroxyethyl)-6-methyl-2-(1H)-pyridinone by biotransformation 29 1992
 
NESTEC S.A. (1)
6309868 Cloning of the prolyl-dipeptidyl-peptidase from Aspergillus oryzae 28 2000
 
FondaTech Benelux N.V. (1)
6090786 Serine proteases, their activity and their synthetic inhibitors 51 1997
 
TAKEDA CHEMICAL INDUSTRIES, LTD. (1)
4824848 Pyrazolo[3,4-d]pyrimidine derivatives, their production and use 16 1987
 
DARA BIOSCIENCES, INC. (3)
6258597 Stimulation of hematopoietic cells in vitro 54 1998
6355614 Cyclic boroproline compounds 48 1999
6703238 Methods for expanding antigen-specific T cells 37 2001
 
PHARMACIA CORPORATION (3)
6545170 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors 35 2001
6495544 Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase 35 2001
2005/0014,732 Combination of an aldosterone receptor antagonist and an anti-diabetic agent 28 2004
 
KEYNEUROTEK PHARMACEUTICALS AG (1)
2004/0147,434 Use of enzyme inhibitors of the dipeptidypeptidase iv (ec3.3.14.5) in addition to the aminopeptidase n (ec 3.4.11.2), individually or in a combination thereof, and pharmaceutical preparations thereof for the prevention and/or therapy of ischaemia-caused acute and chronic neurodegenerative process and illnesses, for example 32 2004
 
GEORGIA TECH RESEARCH CORPORATION (1)
5543396 Proline phosphonate derivatives 79 1994
 
ProThera, Inc. (2)
6251391 Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons 33 1999
6447772 Compositions and methods relating to reduction of symptoms of autism 30 1999
 
Cytokinetics, Inc. (1)
7230000 Methods and compositions utilizing quinazolinones 36 2000
 
AJINOMOTO CO., INC. (1)
5811278 Dipeptidyl peptidase IV from Xanthomonas maltophilia and process for producing the same 26 1996
 
SCHERING CORPORATION (1)
6664273 Piperidine based MCH antagonists for treatment of obesity and CNS disorders 27 2002
 
SYNX, INC. (1)
2004/0242,566 Dipeptidyl peptidase inhibitors 29 2004
 
FERRING B.V. (4)
5939560 Inhibitors of DP-mediated processes, compositions and therapeutic methods thereof 108 1996
6201132 Inhibitors of DP-mediated processes, compositions, and therapeutic methods thereof 59 1999
6521644 Compositions for promoting growth 29 2002
2004/0209,891 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV 30 2004
 
B.M.R.A. Corporation B.V. (1)
6337069 Method of treating rhinitis or sinusitis by intranasally administering a peptidase 27 2001
 
VTVX HOLDINGS II LLC (1)
6673829 Aminoazetidine,-pyrrolidine and -piperidine derivatives 33 2002
 
DRUCKER, DANIEL (2)
6803357 Method of regulating glucose metabolism, and reagents related thereto 65 2001
2003/0153,509 Method of regulating glucose metabolism, and reagents related thereto 65 2002
 
TAISHO PHARMACEUTICAL CO., LTD. (1)
2004/0072,892 Cyanopyrrolidine derivatives 63 2003
 
NOVO NORDISK A/S (10)
6458924 Derivatives of GLP-1 analogs 106 1999
6380398 Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV 56 2001
6645995 Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV 48 2002
2003/0203,946 Glucagon antagonists/inverse agonists 38 2002
2003/0186,963 Substituted piperidines 28 2002
2003/0171,411 Amide derivatives as therapeutic agents 55 2002
2003/0144,206 Combined use of a GLP-1 compound and modulator of diabetic late complications 35 2002
2003/0199,528 Hetrocyclic compounds that are inhibitors of the enzyme DPP-IV 110 2003
2003/0236,272 Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states 89 2003
2004/0054,171 Polymorphic forms of a 4H-thieno[3,2-E]-1,2,4-thiadiazine 1,1-dioxide derivative 28 2003
 
RODOB DRUG RESEARCH INC. (1)
5624894 Brain-enhanced delivery of neuroactive peptides by sequential metabolism 70 1995
 
Cytovia, Inc. (2)
6342611 Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof 38 1998
6335429 Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof 52 2000
 
KISSEI PHARMACEUTICAL CO., LTD. (1)
2004/0138,148 Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof 61 2004
 
ASTRAZENECA AB (1)
6395767 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method 116 2001
 
Boehringer Ingelheim Pharmaceuticals, Inc. (1)
2003/0103,968 Use of alpha specific antibody BIBH1 in the treatment of cancer 30 2002
 
ICOS CORPORATION (1)
6518277 Inhibitors of human phosphatidylinositol 3-kinase delta 128 2001
 
THE GENERAL HOSPITAL CORPORATION (1)
5614492 Insulinotropic hormone GLP-1 (7-36) and uses thereof 164 1993
 
Ortho-McNeil Pharmaceutical, Inc. (1)
6686337 Combination therapy comprising anti-diabetic and anticonvulsant agents 57 2001
 
TRUSTEES OF TUFTS COLLEGE (2)
5965532 Multivalent compounds for crosslinking receptors and uses thereof 69 1997
6825169 Inhibitors of dipeptidyl-aminopeptidase type IV 39 1997
 
DIATIDE, INC. (2)
5366862 Method for generating and screening useful peptides 50 1992
5814460 Method for generating and screening useful peptides 29 1995
 
LES LABORATOIRES SERVIER (3)
6620910 Peptide compounds analogues of the glucagon-like peptide-1 (7-37) 62 1999
6716843 Alpha-amino acid sulphonyl compounds 48 2002
6706742 Alpha-amino-acid compounds 53 2002
 
ABBVIE INC. (1)
2004/0259,843 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) 33 2004
 
DR. REDDY'S LABORATORIES LIMITED (3)
5885997 Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases 50 1996
5985884 Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases 49 1997
6310069 Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases 28 2000
 
THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (2)
6573096 Compositions and methods for inhibition of cancer invasion and angiogenesis 37 2000
2002/0132,979 Compositions and methods for inhibition of cancer invasion and angiogenesis 35 2001
 
TUFTS UNIVERSITY (4)
4935493 Protease inhibitors 102 1987
5462928 Inhibitors of dipeptidyl-aminopeptidase type IV 91 1993
5580979 Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions 71 1994
6485955 Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease 27 1999
 
DANA-FARBER CANCER INSTITUTE, INC. (2)
6325989 Form of dipeptidylpeptidase IV (CD26) found in human serum 34 1995
6265551 Form of dipeptidylpeptidase IV (CD26) found in human serum, antibodies thereto, and uses thereof 37 1996
 
KYOWA HAKKO KOGYO CO., LTD. (1)
2004/0180,925 Dipeptidylpeptidase-IV inhibitor 101 2003
 
Guilford Pharmaceuticals, Inc. (1)
2004/0152,745 Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors 39 2003
 
ROYALTY PHARMA COLLECTION TRUST (2)
6303661 Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals 186 1998
6319893 Raising blood sugar level in hypoglycemic mammals by administering inhibitors of dipeptidyl peptidase IV 57 1999
 
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai (1)
6214340 Physiologically active substance sulphostin, process for producing the same, and use thereof 25 2000
 
AMGEN INC. (1)
5601986 Assays and devices for the detection of extrahepatic biliary atresia 35 1994
 
SAINT LOUIS UNIVERSITY (1)
6261794 Methods for identifying inhibitors of methionine aminopeptidases 29 1999
 
VANDERBILT UNIVERSITY (1)
6586198 Method of identifying susceptibility to angiotensin converting enzyme inhibto- and vasopeptidase-inhibitor-associated angioedema 28 2001
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

  • No Forward Cites to Display

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 11, 2020
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 11, 2024
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00